Exact Sciences announced recently that it acquired PreventionGenetics, a clinical DNA testing laboratory located in Marshfield, Wis. According to a release, PreventionGenetics will provide the clinical lab, expertise and technology…
Exact Sciences and Jefferson Health are collaborating to conduct research on a new blood-based, multi-cancer earlier detection (MCED) test, the company announced recently. According to a release, the joint effort…
Exact Sciences has acquired Ashion Analytics to help accelerate the development of its precision oncology portfolio, including minimal residual disease (MRD) and other sequencing-based tests, the company announced recently. According…
Exact Sciences announced today it will acquire Thrive Earlier Detection Corp. for $2.15 billion and Base Genomics for an undisclosed sum. Both companies specialize in cancer screening blood tests. According to…
Exact Sciences has introduced its Oncotype MAP Pan-Cancer Tissue test for patients with advanced, metastatic, refractory or recurrent cancer, the company announced today. According to a release, the Oncotype MAP…
Exact Sciences has extended and made amendments to its agreement with Pfizer to promote Cologuard, the company announced recently. “We’re thrilled to continue working with Pfizer to increase screening rates with…
Exact Sciences‘ Oncotype DX Genomic Prostate Score (GPS) test is a strong independent predictor of critical outcomes in UFI-risk prostate cancer patients, the company announced today. The results of the study–which included 299…
Exact Sciences is one of four organizations to participate in Gov. Tony Evers’ new public-private partnership to increase Wisconsin’s laboratory testing capacity for COVID-19, the governor announced recently. According to…
Exact Sciences has acquired Paradigm Diagnostics and Viomics to extend its lab testing and research and development capabilities, the company announced recently. According to a release, Paradigm offers a comprehensive…
The U.S. Food and Drug Administration approved Exact Sciences‘ Cologuard for use by eligible average-risk individuals ages 45 and older, the company announced today. Previously, the FDA had approved use…
